Wijdicks E
Neurocrit Care. 2022; .
PMID: 36289157
DOI: 10.1007/s12028-022-01621-0.
Li L, Sassen S, van der Jagt M, Endeman H, Koch B, Hunfeld N
Pharmaceutics. 2022; 14(3).
PMID: 35335925
PMC: 8950491.
DOI: 10.3390/pharmaceutics14030549.
Fukata S, Kawabata Y, Fujisiro K, Katagawa Y, Kuroiwa K, Akiyama H
Surg Today. 2014; 44(12):2305-13.
PMID: 24532143
DOI: 10.1007/s00595-014-0859-7.
Wang E, Mabasa V, Loh G, Ensom M
Neurocrit Care. 2011; 16(1):170-83.
PMID: 22038577
DOI: 10.1007/s12028-011-9643-3.
Finnegan P, Buckingham R
Can Fam Physician. 2011; 26:1199-202.
PMID: 21293683
PMC: 2383698.
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.
Miller R
Curr Neuropharmacol. 2010; 7(4):302-14.
PMID: 20514210
PMC: 2811864.
DOI: 10.2174/157015909790031229.
Pharmacokinetics of haloperidol: an update.
Kudo S, Ishizaki T
Clin Pharmacokinet. 2000; 37(6):435-56.
PMID: 10628896
DOI: 10.2165/00003088-199937060-00001.
Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.
Wagner B, OHara D
Clin Pharmacokinet. 1998; 33(6):426-53.
PMID: 9435992
DOI: 10.2165/00003088-199733060-00003.
Pharmacokinetic optimisation of the treatment of psychosis.
Balant L, Andreoli A
Clin Pharmacokinet. 1993; 25(3):217-36.
PMID: 7900948
DOI: 10.2165/00003088-199325030-00005.
Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.
Seiler W, WETZEL H, Hillert A, Schollnhammer G, Langer M, Barlage U
Psychopharmacology (Berl). 1994; 116(4):457-63.
PMID: 7701049
DOI: 10.1007/BF02247478.
Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.
Milton G, Jann M
Clin Pharmacokinet. 1995; 28(6):494-504.
PMID: 7656507
DOI: 10.2165/00003088-199528060-00007.
Radioimmunoassay of bromperidol and haloperidol in human and canine plasma.
Van den Eeckhout E, Belpaire F, Bogaert M, de Moerloose P
Eur J Drug Metab Pharmacokinet. 1980; 5(1):45-8.
PMID: 7389751
DOI: 10.1007/BF03189443.
On the distribution and elimination of haloperidol in cholecystectomized patients.
Forsman A, Larsson M, Lundborg H, Renstrom P
Eur J Drug Metab Pharmacokinet. 1981; 6(4):249-53.
PMID: 7333324
DOI: 10.1007/BF03189521.
Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.
Rowell F, Hui S, Fairbairn A, Eccleston D
Br J Clin Pharmacol. 1981; 11(4):377-82.
PMID: 7259931
PMC: 1401662.
DOI: 10.1111/j.1365-2125.1981.tb01135.x.
Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
Moulin M, Davy J, Debruyne D, Andersson J, Bigot M, Camsonne R
Psychopharmacology (Berl). 1982; 76(4):346-50.
PMID: 6812109
DOI: 10.1007/BF00449123.
Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
Rimon R, Averbuch I, Rozick P, Kara T, Dasberg H, Ebstein R
Psychopharmacology (Berl). 1981; 73(2):197-9.
PMID: 6785816
DOI: 10.1007/BF00429218.
High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich I
Psychopharmacology (Berl). 1980; 67(1):17-23.
PMID: 6768075
DOI: 10.1007/BF00427590.
Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
Eisele R, Balant L, Garrone G
Eur Arch Psychiatry Neurol Sci. 1984; 234(1):1-4.
PMID: 6489392
DOI: 10.1007/BF00432875.
Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Beresford R, Ward A
Drugs. 1987; 33(1):31-49.
PMID: 3545764
DOI: 10.2165/00003495-198733010-00002.
Pharmacokinetics of haloperidol in psychotic patients.
Cheng Y, Paalzow L, Bondesson U, Ekblom B, Eriksson K, ERIKSSON S
Psychopharmacology (Berl). 1987; 91(4):410-4.
PMID: 3108922
DOI: 10.1007/BF00216005.
